44 2033180199
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Clinical Nephrology and Research

Sign up for email alert when new content gets added: Sign up

A case of SIADH escape to tolvaptan from small cell lung cancer.

Author(s): Lakshmi Kannan*

BACKGROUND: Syndrome of inappropriate antidiuresis is characterized by euvolemic hyponatremia due to inappropriate secretion or elevation of antidiuretic hormone or arginine vasopressin. Patients with small cell lung cancer are especially prone for this complication and multiple randomized control trials have shown an improvement in sodium with tolvaptan.

CASE: We report a 61-year-old-male patient with small cell lung cancer who presented with to the hospital multiple times with acute on chronic symptomatic hyponatremia. The patient showed a good response to tolvaptan but subsequently developed resistance as a result of progression of lung cancer with metastasis to liver.

CONCLUSION: In cases of paraneoplastic effects of lung cancer, hyponatremia is an important manifestation from syndrome of inappropriate antidiuresis. Hyponatremia, in these patients, is associated with significant morbidity and mortality and treatment includes surgery, chemotherapy or radiation therapy for the cancer, tolvaptan for hyponatremia and in cases of progression of cancer, addition of salt tablets or loop diuretics may be necessary

Google Scholar citation report
Citations : 361

Clinical Nephrology and Research received 361 citations as per Google Scholar report

Global Tech Summit Top